Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases
Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases
复制标题
DOI：
10.1016/j.ijrobp.2016.01.037
复制
发表时间：
2016-06-01
影响因子：
7
通讯作者：
Chiang, Veronica L.
中科院分区：
文献类型：
--
作者：
Magnuson, William J.;Yeung, Jacky T.;Chiang, Veronica L.
目的：对发生脑转移（BM）的表皮生长因子受体（EGFR）突变型肺腺癌患者进行回顾性分析，以评估我们的假设，即使用前期EGFR酪氨酸激酶抑制剂（TKI）和延迟放射治疗（RT）将导致较低的颅内无进展生存率，但总生存率（OS）相似。方法和材料：在2008年7月1日至2014年12月31日期间诊断为EGFR突变型NSCLC的202例患者中，71例发生BM。21名患者因既往使用EGFR-TKI、EGFR-TKI耐药突变、全脑放射治疗（WBRT）/立体定向放射外科（SRS）后未能接受EGFR-TKI或
Purpose: To perform a retrospective analysis of patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma who developed brain metastases (BM) to evaluate our hypothesis that the use of upfront EGFR-tyrosine kinase inhibitors (TKIs), and deferral of radiation therapy (RT), would result in inferior intracranial progression-free survival but similar overall survival (OS).Methods and Materials: Of 202 patients diagnosed with EGFR-mutant NSCLC between July 1, 2008, and December 31, 2014, 71 developed BM. Twenty-one patients were excluded owing to prior EGFR-TKI use, EGFR-TKI resistance mutation, failure to receive EGFR-TKI after whole-brain radiation therapy (WBRT)/stereotactic radiosurgery (SRS) or